Compare BNED & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNED | FHTX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.2M | 360.8M |
| IPO Year | N/A | 2020 |
| Metric | BNED | FHTX |
|---|---|---|
| Price | $9.12 | $5.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.43 |
| AVG Volume (30 Days) | ★ 376.7K | 195.7K |
| Earning Date | 01-20-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $1,677,191,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $40.91 |
| Revenue Next Year | N/A | $11.87 |
| P/E Ratio | $189.19 | ★ N/A |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $5.90 | $2.95 |
| 52 Week High | $12.21 | $6.95 |
| Indicator | BNED | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 55.22 |
| Support Level | $8.65 | $5.55 |
| Resistance Level | $9.70 | $6.29 |
| Average True Range (ATR) | 0.45 | 0.48 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 66.28 | 47.19 |
Barnes & Noble Education Inc is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also a textbook wholesaler and inventory management hardware and software provider. It offers course materials through physical and online bookstores, including new and used print textbooks, rental options, digital textbooks, and publisher-hosted digital courseware. Products are also offered directly to students through Textbooks.com. The majority of the company's revenue is derived from the sale of products through its bookstore locations, including virtual bookstores, and the bookstore affiliated e-commerce websites.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.